Nancy T. Chang

Chang Tang Chang (born 1950), née Tang Nanshan (Chinese: 唐南珊; pinyin: Táng Nánshān), is a biochemist who cofounded Tanox in 1986 to address medical needs in the areas of allergy, asthma, inflammation and diseases affecting the human immune system. Tanox took an innovative approach in developing an asthma drug that focused on the allergy-related basis of asthma, Xolair. In June 2003, the U.S. Food and Drug Administration (FDA) approved Xolair, the first biotech product cleared for treating those with asthma related to allergies. Tanox was also active in the development of TNX-355, an antibody for the treatment of HIV/AIDS. In 2007, Tanox was sold to Genentech for $919 million. Chang grew Tanox from an idea to a substantial publicly traded company, doing innovative science. Following her success with Tanox, she has become an angel investor in health-care entrepreneurships and performs philanthropic work in community health-education projects.

Nancy Chang
唐南珊
Nancy Chang, 2012
Born	1950 (age 73–74) Taiwan
Alma mater	National Tsing Hua University (BS) Brown University (BA) Harvard University (PhD)
Known for	Xolair
Awards	Biotechnology Heritage Award
Scientific career
Fields	Biotechnology, Biochemistry
Institutions	Tanox

External videos
Nancy Chang, "Do the things you really wanted to do, that really matters to you, because then all the hardships become irrelevant.", Science History Institute

Biography

Chang was born in Taiwan in 1950. Her parents were from mainland China, and had traveled to Taiwan after their marriage. Due to political unrest in China, they were not allowed to return, and stayed in Taiwan. Chang attended Taipei First Girls' High School in Taipei, where "we were trained to compete with the boys". She studied college chemistry the first year in high school and college physics the second year.

Chang attended Taiwan's National Tsing Hua University, where she took undergraduate classes from future Nobel Prize winner Yuan T. Lee. There she also met a fellow scientist, Tse Wen Chang. They married just a few days before traveling to the United States, where both had received scholarships for graduate school: Chang at Brown University and Tse Wen at Harvard University. Chang also completed additional undergraduate studies at Brown University.

On the plane ride to the United States, Chang read James Watson’s book on the discovery of the double helix. This sparked her interest in biology, which she had not previously studied. Chang subsequently changed her academic focus to biology and transferred to the Division of Medical Sciences, Harvard University. The Changs were among the first international students at the Division of Medical Sciences, and Chang had to work extremely hard due to her unfamiliarity with English. Chang earned her Ph.D. in biological chemistry from Harvard University.

Work

Her interest in interferon led her to approach Sidney Pestka at Roche Pharmaceutical Company and be hired at Hoffman-La Roche. For a time, the Changs endured the difficulties of a commuter marriage: Chang lived and worked in Parsippany, NY; Tse Wen commuted to Pennsylvania each week to work at Centocor. Eventually Chang joined Centocor as a bench-level diagnostician. Her heart was still in research, and she took part in Centocor's involvement in therapeutic research. She brought in several new projects, including HIV/AIDS research. Nancy's team participated in a consortium, which sequenced the HIV genome structure. Chang was instrumental in developing the first diagnostic assay to detect HIV infection by employing a peptide segment of HIV as the solid-phase antigen in the immunoassay. She was Director of Research at Centocor from 1982 to 1986.

In 1986, the Changs moved to Houston, TX. Baylor College of Medicine in Houston offered Tse Wen a faculty position, and Chang was able to obtain a position as well. She became Associate Professor of Virology at Baylor College of Medicine, serving from 1986 to 1991.

Both Chang and Tse Wen suffered severely from allergies. Tse Wen had an idea for treating allergies by blocking IgE (immunoglobulin E), and the Changs founded the biotechnology company Tanox. Tse Wen continued his preferred work as a professor, and Chang served as president of the new company. In 1992, the Changs separated. Tse Wen returned to Taiwan in 1996 to teach, while remained as a board member of Tanox until the company was acquired by Genentech. Chang continued her work with Tanox, serving as CEO as well as president.

Tanox focused on addressing medical needs in the areas of allergy, asthma, inflammation, and diseases affecting the human immune system, developing an asthma drug that targeted the allergy-related basis of asthma, Xolair. Tanox's initial public offering in 2000 was the second largest IPO ever for a biotechnology company, raising $244 million. In June 2003, the U.S. Food and Drug Administration (FDA) approved Xolair, the first biotech product cleared for treating those with asthma related to allergies. In 2007, Tanox was sold to Genentech for $919 million. Chang continued to be involved, as chairman of Tanox's board of directors.

Tanox was also active in the development of TNX-355, an antibody for the treatment of HIV/AIDS. Chang has said that she is passionate about AIDS because of her work as a young researcher in one of the first laboratories to confront the disease.

Chang Chang's published research includes over 35 papers on topics including monoclonal antibodies and HIV. She has been awarded seven patents.

Chang has served on the boards of directors of the Federal Reserve Bank in Houston, of BioHouston, of Project Hope, of Charles River Laboratories, and of the Board of Visitors of the University of Texas M.D. Anderson Cancer Center, among others. Chang is an angel investor in health-care entrepreneurships and performs philanthropic work in community health-education projects. As part of Project Hope's China programs, she has had the responsibility of assessing annual progress in programs at Wuhan University School of Medicine, Shanghai Children's Medical Center, and educational programs and treatments for diabetes and HIV/AIDS. As of 2009, Chang was the chairman and managing director of OrbiMed's Caduceus Asia partner fund and a member of Orbimed Advisors, the largest investment firm focused entirely on the healthcare sector. As of 2013, Chang Chang was president of Apex Enterprises.

Honors and awards

During her career, Chang has received numerous academic, national and international awards for her leadership and contributions to the biopharmaceutical industry.

Chang Chang was inducted into the Texas Science Hall of Fame in 2001, for exemplary achievement in science.

In 2005, she was named a Most Respected Woman in Biotechnology (MedAd News, 2005), and also received the Global Business Achievement Hall of Fame Governor's Award from the Global Federation of Chinese Business Women in the Southern U.S.

In 2008 Chang was named to the Forbes Twenty-Five Notable Chinese Americans list.

In 2012, she became the first woman to receive the 14th annual Biotechnology Heritage Award, conferred by the Biotechnology Industry Organization (BIO) and the Chemical Heritage Foundation.

She is the recipient of several additional awards, such as the Association of Women in Computing: Top 20 Houston Women in Technology and Houston Entrepreneur of the Year.

External links

• Chang Chang, Video, 15 min 35 sec, from Women in Chemistry, at the Science History Institute, Philadelphia, PA